Mei‐Kim Ang

3.5k total citations
64 papers, 1.3k citations indexed

About

Mei‐Kim Ang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Mei‐Kim Ang has authored 64 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 19 papers in Otorhinolaryngology. Recurrent topics in Mei‐Kim Ang's work include Lung Cancer Treatments and Mutations (30 papers), Head and Neck Cancer Studies (19 papers) and Lung Cancer Research Studies (10 papers). Mei‐Kim Ang is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Head and Neck Cancer Studies (19 papers) and Lung Cancer Research Studies (10 papers). Mei‐Kim Ang collaborates with scholars based in Singapore, United States and China. Mei‐Kim Ang's co-authors include Wan‐Teck Lim, Daniel Shao-Weng Tan, Eng Huat Tan, Quan‐Sing Ng, Balram Chowbay, Khee‐Chee Soo, Chee‐Keong Toh, Joseph Wee, N. Gopalakrishna Iyer and Quan Sing Ng and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mei‐Kim Ang

61 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mei‐Kim Ang Singapore	19	658	473	411	372	372	64	1.3k
Christian Borel France	23	1.2k 1.8×	496 1.0×	386 0.9×	348 0.9×	494 1.3×	78	1.9k
Anastasia G Eleftheraki Greece	20	612 0.9×	316 0.7×	205 0.5×	357 1.0×	240 0.6×	37	1.2k
L. Geoffrois France	20	519 0.8×	555 1.2×	420 1.0×	358 1.0×	171 0.5×	55	1.2k
Charles Schneider United States	17	654 1.0×	301 0.6×	258 0.6×	260 0.7×	282 0.8×	45	993
Stella Y. Tsai Taiwan	19	471 0.7×	373 0.8×	423 1.0×	157 0.4×	325 0.9×	25	1.3k
Sergi Benavente Spain	15	931 1.4×	545 1.2×	137 0.3×	523 1.4×	190 0.5×	33	1.4k
Anna Kalogera‐Fountzila Greece	23	814 1.2×	460 1.0×	624 1.5×	196 0.5×	255 0.7×	68	1.5k
Chan-Young Ock South Korea	21	1.0k 1.6×	508 1.1×	124 0.3×	309 0.8×	255 0.7×	42	1.4k
Mengzhong Liu China	22	749 1.1×	803 1.7×	674 1.6×	431 1.2×	335 0.9×	77	1.9k
Julia Kitz Germany	22	564 0.9×	280 0.6×	76 0.2×	426 1.1×	296 0.8×	52	1.2k

Countries citing papers authored by Mei‐Kim Ang

Since Specialization

Citations

This map shows the geographic impact of Mei‐Kim Ang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei‐Kim Ang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei‐Kim Ang more than expected).

Fields of papers citing papers by Mei‐Kim Ang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei‐Kim Ang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei‐Kim Ang. The network helps show where Mei‐Kim Ang may publish in the future.

Co-authorship network of co-authors of Mei‐Kim Ang

This figure shows the co-authorship network connecting the top 25 collaborators of Mei‐Kim Ang. A scholar is included among the top collaborators of Mei‐Kim Ang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei‐Kim Ang. Mei‐Kim Ang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saw, Stephanie P.L., Gillianne Lai, Landon L. Chan, et al.. (2024). Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC. Lung Cancer. 193. 107856–107856. 4 indexed citations

Tay, Timothy Kwang Yong, Enya H.W. Ong, Michael Fehlings, et al.. (2024). Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer. European Thyroid Journal. 13(1). 8 indexed citations

Ong, Enya H.W., Jingjing Miao, Joseph Wee, et al.. (2023). Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma. Oral Oncology. 148. 106655–106655. 10 indexed citations

Yeo, Eugenia L.L., Enya H.W. Ong, Joe Yeong, et al.. (2023). Association of Claudin-1 overexpression with immune exclusion in nasopharyngeal carcinoma and its potential as a novel therapeutic target.. JCO Global Oncology. 9(Supplement_1). 151–151. 1 indexed citations

Lim, Wan‐Teck, Hsiang‐Fong Kao, Lisda Suteja, et al.. (2023). Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nature Communications. 14(1). 2781–2781. 25 indexed citations

Tan, Wan Ling, Sze Huey Tan, Daniel S.W. Tan, et al.. (2023). EP12.01-31 Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer. Journal of Thoracic Oncology. 18(11). S652–S653.

Saw, Stephanie P.L., Mei‐Kim Ang, & Daniel S.W. Tan. (2022). Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions. Current Treatment Options in Oncology. 23(12). 1721–1731. 10 indexed citations

Ang, Mei‐Kim, Ekkasit Tharavichitkul, Cindy Lim, et al.. (2021). Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head & Neck. 43(5). 1641–1651. 10 indexed citations

Ang, Mei‐Kim & Tony Mok. (2019). Twenty‐five years of Respirology: Advances in lung cancer. Respirology. 25(1). 26–31. 2 indexed citations

10.

Tan, Sze Huey, Wan‐Teck Lim, Eng Huat Tan, et al.. (2019). Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). PLoS ONE. 14(11). e0224665–e0224665. 21 indexed citations

11.

Tan, E.H., Wan‐Teck Lim, Mei‐Kim Ang, et al.. (2018). Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore. Annals of Oncology. 29. ix161–ix161. 5 indexed citations

12.

Ng, Quan Sing, Cindy Lim, Eng Huat Tan, et al.. (2018). Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer. 18(1). 1198–1198. 19 indexed citations

13.

Tan, Daniel Shao-Weng, Fui Teen Chong, Hui Sun Leong, et al.. (2017). Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nature Medicine. 23(10). 1167–1175. 132 indexed citations

14.

Chan, Sock Hoai, Weng Khong Lim, Scott T. Michalski, et al.. (2016). Germline hemizygous deletion of CDKN2A–CDKN2B locus in a patient presenting with Li–Fraumeni syndrome. npj Genomic Medicine. 1(1). 16015–16015. 9 indexed citations

15.

Zhang, Zhenxian, Eng Huat Tan, Mei‐Kim Ang, et al.. (2016). Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules. PLoS ONE. 11(5). e0154316–e0154316. 14 indexed citations

16.

Ang, Mei‐Kim, et al.. (2016). Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report. Radiology Case Reports. 11(3). 245–247. 11 indexed citations

17.

Tan, Eng Huat, Daniel S.W. Tan, Benjamin Haaland, et al.. (2015). Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer. 88(3). 289–296. 17 indexed citations

18.

Tan, E.H., Wan‐Teck Lim, Khee Chee Soo, et al.. (2011). Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Annals of Oncology. 23(4). 1010–1016. 18 indexed citations

19.

Ngeow, Joanne, Wan‐Teck Lim, Swan Swan Leong, et al.. (2010). Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Annals of Oncology. 22(3). 718–722. 53 indexed citations

20.

Ang, Mei‐Kim, et al.. (2008). A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematology/Oncology and Stem Cell Therapy. 1(3). 159–165. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact